PATIENT POPULATION Sample Clauses

PATIENT POPULATION. Ages/Ratio: Adult Diagnoses: Anxiety. Depression. SMI. PTSD. Schizophrenia. Bi-Polar. Chronic & Persistently Mentally Ill. Referral Sources: How Patients are Seen (phone, video from home, video from clinic, etc.): Languages: None

PATIENT POPULATION. BioForm expects to implement standard inclusion and exclusion criteria to screen a population of evaluable patients for this study. **** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

PATIENT POPULATION. This collaborative practice agreement will apply to all patients referred to PHARMACIST, RPh by PHYSICIAN, MD. It will be understood that all such patients referred to PHARMACIST, RPh will have an established physician-patient relationship with PHYSICIAN, MD and that the referred patient requires LAIA treatment.

PATIENT POPULATION. We identified 99 consecutive new referrals to the local interstitial lung disease unit who did not receive a diagnosis of IPF. There were 56 patients excluded: established diagnosis of CTD at the time of referral (n=23), presentation HRCT or PFTs not available (HRCT unavailable, n=20, PFTs unavailable, n=1), DLco<30% predicted (n=9), referral not for suspected ILD (n=8). The remaining 38 patients were included in the study. We identified 58 consecutive new referrals to the local interstitial lung disease unit who received a diagnosis of IPF. There were 36 patients excluded: presentation HRCT or PFTs not available (n=17), DLco<30% predicted (n=19). The remaining 22 patients were included in the study. Therefore, the total cohort was made up of 60 patients (Figure A1). Patient diagnoses (following evaluation at the Royal Brompton Hospital, UK) are shown in the Table A4. Five patients required surgical lung biopsy. Three of these were diagnosed as IPF, one as pulmonary alveolar proteinosis and one as obliterative bronchiolitis. Vital status was known for all patients at the end of the study period. There were 26/60 (43·4%) deaths at the end of the study period. 16/22 (72.7%) IPF cases died at the end of the study period. Mean follow-up period for IPF and non-IPF cases were 1246.0 days and 1646.0 days respectively.

PATIENT POPULATION. Male or female patients >18 to <75 of age with moderate to severe, stable, active plaque Psoriasis Vulgaris affecting between 10% to 30% of the body surface and with a Psoriasis Area and Severity Index (PASI) score of 10 to 20 Efficacy Objective: To examine the effect of treatment with two different doses of VB-201 compared to placebo for 16 weeks and 24 weeks on measures of disease activity in patients with psoriasis.

PATIENT POPULATION. This collaborative practice agreement will apply to all patients referred to (Pharmacist) by their referring primary care physician.

PATIENT POPULATION. ○ Moderate to severe Crohn’s Disease patients with objective inflammation and distal disease at baseline ● CDAI 220-350 (also consider broader range of 220-450), and ● Elevated CRP OR fecal calprotectin (FCP) OR mucosal ulceration ● To be discussed: thresholds of CRP, FC that will maximize enrollment of patients with active endoscopic disease? ● To be discussed: require minimum mucosal involvement of one segment to avoid criticism of subjects with negative mucosal evidence yet meeting CDAI criteria? (i.e. require SES-CD score of >=3?) ● To be discussed: Possible requirement for stool frequency and abdominal pain: SF>=4 and AP >=2 (tentative inclusion unless significant impact on enrolment projections) ○ Having failed one biologic agent (anti-TNF, vedolizumab, etc; just one MOA failure) ○ TBC: 150 mg BID vs placebo, oral formulation ○ Adaptive design: Automatic down-dosing to 100 mg BID if the safety lab elevations (ALT, CPK, WBC, etc) were significantly higher than expected ● Thresholds TBD

PATIENT POPULATION. Patients are identified by searching the Emory electronic medical record system (Powerchart) that includes data on all patients followed at Emory University Hospitals. We reviewed the electronic charts of all patients admitted to the Emory Hospitals age ≥ 18 with primary diagnosis of worsening HF since January 2012. First consecutive eligible 100 subjects that had an all cause 30-day readmission are included in analysis for the study. The data in regards to patients demography, cause of admission, treatment and discharge at the time of admission, prior admissions and presence of comorbid conditions like diabetes, hypertension, Kidney disease, COPD, Ejection Fraction (EF) are collected and analyzed for preventable vs non preventable causes of readmission . Data was collected using the Emory electronic medical record (Powerchart). Patients admitted at Emory University Hospitals with primary diagnosis of HF are screened and the first 100 patients that had all cause 30-day readmission are identified and are included in the study. Data collected from Powerchart also included demographic factors, cause of admission, treatment and discharge at the time of admission, prior admissions and presence of comorbid conditions like diabetes, hypertension, Kidney disease, COPD, Ejection Fraction (EF), date of initial admission, date of readmission. Patients with all cause 30-day readmission were analyzed for their cause for readmission. The preventable causes for this study included inadequate treatment during the prior hospitalization, inadequate discharge plan and follow up and inadequate treatment of the comorbid conditions that might have precipitated the readmission. The non-preventable causes included unavoidable progression of chronic disease, patient’s non-compliance to diet and drugs due to socio economic and psychological factors like insurance, depression and lack of social support. All stored data is encrypted and organized with the use of a coding system in an excel spreadsheet. The excel spread sheet was stored in a shared drive that had restricted access with user id and password and also in an encrypted computer. The study was conducted after approval of Emory University Institutional Review Board (IRB). The study qualified for a complete HIPAA waiver from Emory IRB because the study is a retrospective chart review study. Children (under the age of 18 years old) are not included in the study. This is a minimal risk study, as the only risks to those who part...

PATIENT POPULATION. For the present study, we selected subjects who had representative EUS-nCLE videos and a definitive histopathologic diagnosis of the most prevalent PCLs (IPMN, MCN, SCA, pseudocyst, SPN, cystic-NET). A total of 76 subjects fulfilled eligibility criteria and were included.